03.06.2018 Issue 392

Visit HealthEconomics.Com Subscribe to Newsletters  |  Contact Us  |  Forward to a Friend
Sponsored by:

This Week's HEOR Round-up
The Top Story in HEOR: Latest Headlines in HEOR:

Growing Use of RWE Carries Pros, Cons

Sunday, March 4, 2018

While real-world evidence is a powerful tool in the health industry, it’s also raised some concerns about personal privacy.

Institute Looks to Use Cancer Data to Change Payment Paradigms

Partnership of Titans Looks Beyond Lower Drug Prices

Column: Employers Should Explore Outcomes-Based Contracts

AMCP Forum Focused on Patient-Reported Outcomes

Waxman: Target Cost Drivers to Reach Consensus on Drug Pricing

NICE’s HST to Review 4 New Rare Disease Treatments

Pfizer, Patients as Partners Executive Speak on Podcast

Report Finds Sizeable Digital Trust Gap

Associate Director, Field HEOR - Managed Care (Colorado)

Senior Research Analyst - ID: 127317BR

Associate Director, Strategic Market Access- CAR-T

Associate Healthcare Outcomes Solutions Director

Market Access / Health Economics Manager, Ireland. €50k-€60k

Health Economics and Market Access (Senior) Consultant, Cambridge, UK

Research Scientist - Outcomes Research/Health Preferences

Industry Spotlight

Conferences Webinars

National Health Policy Conference 2018
    March 7-8, Washington

Orphan Drugs & Rare Diseases Global Congress 2018 Europe
    March 7-9, London

Research Techniques for Value Based Pricing
    March 12-13, Amsterdam

Remap Consulting Market Access Training Workshops
    March 14-15, Boston

Medicaid: Adapt to the Changes
    March 6

Bringing the Inside Out: Chart Abstraction Methodologies that Integrate Physician Insights
    March 13

Tailored to Translate: Custom Preclinical Models for Advancing Diverse Therapeutic Strategies in Oncology
    March 14

EVDAS Outputs are Available to MAHs – What Now?
    March 15

Conference of the Week Webinar of the Week Job of the Week Link of the Week

Syndicated Reports White Papers
Biosimilars: E.U. Payer Perspectives

MSL Teams: Field Force Size and Structure

Market Access Impact: Type 2 Diabetes Mellitus (Injectables) (US) 2017

Market Access Impact: Type 2 Diabetes Mellitus (Orals) (US) 2017

Market Access Impact: Rheumatoid Arthritis (US) 2017

Reforming Biopharmaceutical Pricing at Home and Abroad

U.S. Presidential Mandate on Value-based Drug Pricing: Moonshot or Wormhole?

The State of Digital Identification and Signatures

Secure Document Workflows in Drug Development

Streamline Regulatory Compliance in Life Sciences with Digital Transaction Management

Special Thanks to Our Partners:
Evidence Partners  Evidera    eyeforpharmaG&J Lee RecruitmentHealthCore
  MAPS    University of FL    IQVIA    TruvenXcenda
OM1ParexelICON Jefferson  Dymaxium
  Curo  PharmeritDRG AbacuseMax Health